ERBB2 and breast cancer: In keeping with the significant impact on pCR that dual anti-HER2 therapy has shown [26–28], we also identified a higher pCR rate for NACT with dual anti-HER2 therapy compared to NACT with single ani-HER2 therapy in patients with IHC 3+ BC.